于江,肖虹,刘宇

• 1:中国中医科学院西苑医院
• 2:北京中医药大学
• 3:北京中医药大学东直门医院

摘要(Abstract)：

目的探讨冠心病患者择期冠状动脉介入术后造影剂肾病(CIN)与中医证型的分布规律及相关性。方法采用回顾性研究的调查方法,按纳入标准及排除标准收集中国中医科学院西苑医院临床病例共466例,依据术后是否发生CIN分为CIN组与非CIN组,记录患者基础资料、生化、手术、中医四诊、辨证分型等相关信息。观察分析CIN患者的中医证型分布特点,比较各中医证型患者经皮冠脉介入术(PCI)术后肾功能变化,分析CIN的危险因素。结果CIN患者的中医证型分布由多到少依次为阳气虚衰证、心肾阳虚证、寒凝血瘀证、气虚血瘀证、痰瘀互阻证、心肾阴虚证、气阴两虚证、心血瘀阻证、气滞血瘀证;不同证型CIN患者术后肾功能变化比较显示阳气虚衰证组与心肾阳虚证组血肌酐升高明显;通过Logistic回归分析提示阳气虚衰证、心肾阳虚证为CIN发生的独立危险因素。结论中医证型阳气虚衰证、心肾阳虚证与CIN的发生高度相关,可作为择期行PCI的冠心病患者发生CIN的预测因素。

关键词(KeyWords)： 造影剂肾病;经皮冠状动脉介入术;中医证型;危险因素

Abstract:

Keywords:

基金项目(Foundation): 中央高校基本科研业务费专项基金资助（2019-JYB-JS-056）

作者(Author): 于江,肖虹,刘宇

参考文献(References)：

• [1] Abe M,Morimoto T,Nakagawa Y,et al. Impact of transient or persistent contrast-induced nephropathy on long-term mortality after elective percutaneous coronary intervention[J].Am J Cardiol,2017,120(12):2146-2153.
• [2] Hossain MA,Costanzo E,Cosentino J,et al. Contrast-induced nephropathy:Pathophysiology,risk factors,and prevention[J]. Saudi J Kidney Dis Transpl,2018,29(1):1-9.
• [3] Zheng X,Curtis J,Hu S,et al. Coronary catheterization and percutaneous coronary Intervention in China:10-year results from the China PEACE-retrospective cathPCI study[J]. JAMAIntern Med,2016,176(4):512-521.
• [4]董加建,陈亚娟，毛幼林.肾阻力指数指导下的水化治疗预防造影剂肾病的临床研究[J].临床心血管病杂志，2019,35(3):278-280.
• [5] Stacul F,van der Molen AJ,Reimer P,et al. Contrast induced nephropathy:updated ESUR contrast Media Safety committee guidelines[J]. Eur Radiol,2011,21(12):2527-2541.
• [6]中国中西医结合学会心血管学会.冠心病中医诊断标准[J].中西医结合杂志，1991,11(5):257.
• [7] Jorgensen AL. Contrast-induced nephropathy:pathophysiology and preventive strategies[J]. Crit Care Nurse,2013,33(1):37-46.
• [8] Yuan Y,Qiu H,Song L,et al. A new risk factor profile for contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention[J].Angiology,2018,69(6):523-531.
• [9]陈文平，冯烈.不同糖代谢及相关因素对造影剂肾病的影响[J].中国糖尿病杂志，2012,20(10):765-767.
• [10] Mamoulakis C,Tsarouhas K,Fragkiadoulaki I,et al. Contrast-induced nephropathy:Basic concepts,pathophysiological implications and prevention strategies[J]. Pharmacol Ther,2017,180:99-112.
• [11]刘勇，姚斌，刘超峰.冠心病心绞痛痰瘀毒互结证病机研究进展[J].中医杂志，2019,60(21):1875-1879.
• [12] Azzalini L,Spagnoli V,Ly HQ. Contrast-Induced nephropathy:from pathophysiology to preventive strategies[J]. Can J Cardiol,2016,32(2):247-255.
• [13] Rancic ZS. Commentary on′contrast induced nephropathy and long-term renal decline after percutaneous transluminal angioplasty for symptomatic peripheral arterial disease[J].Eur J Vasc Endovasc Surg,2016,51(3):394.
• [14] Giacoppo D,Gargiulo G,Buccheri S,et al. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures:Evidence from a hierarchical bayesian network Meta-analysis of 124 trials and 28-240 patients[J]. Circ Cardiovasc Interv,2017,10(5):e004383.
• [15]陈海威，张津津，熊丹，等.肾康注射液对老年慢性肾病患者造影剂肾病的防治作用[J].中国中西医结合杂志，2016,36(7):792-796.